EVE Energy Unveils CR123AP Medical Battery: Innovative Technology for a Better Life

SHANGHAI / JINGMEN – On April 9, the 93rd China International Medical Equipment Fair (CMEF) Spring Edition officially opened. Amid the bustling exhibition floor, EVE Energy made a powerful statement by unveiling its all-new medical-grade battery, the CR123AP. Positioned at the intersection of hardcore innovation and green manufacturing, the new cell is engineered to protect life and health while enabling a better, more sustainable future.

With more than two decades of deep specialization in the medical battery domain, EVE Energy has consistently adhered to a distinctive philosophy: “A battery is a living entity — we treat every cell with reverence.” This mindset has driven the company to build a complete medical battery ecosystem covering implantable devices, in-vitro diagnostics, emergency equipment, and more. As automated external defibrillators (AEDs) rapidly expand into multi-scenario applications and electric surgical staplers undergo continuous performance upgrades, the industry faces stricter demands for battery reliability and environmental adaptability. EVE Energy identified these critical pain points and responded with the CR123AP — an innovative solution designed to address industry-wide challenges and meet the evolving requirements of next-generation medical devices.

As an advanced upgrade tailored for healthcare applications, the CR123AP directly overcomes the limitations of traditional medical batteries, including poor extreme-environment resilience and pulse energy latency. By redefining performance benchmarks, the new cell delivers four core advantages that ensure stable and reliable operation for critical medical equipment:

The breakthrough performance of the CR123AP stems directly from EVE Energy’s proprietary dry electrode process technology. Unlike conventional solvent-based slurry methods, this innovative approach eliminates hazardous solvents, simplifies production via dry forming, and significantly lowers carbon emissions. At the same time, it enhances the electrode’s conductive architecture and mechanical stability. The result is a battery that excels in pulse output strength, low-temperature adaptability, and long-term operational reliability — fully aligned with the strictest medical device standards.

EVE Energy continues to push the boundaries of performance through its evolving technology roadmap: optimizing self-discharge characteristics, extending effective service life, and broadening temperature-range adaptability. Furthermore, AI-powered intelligent inspection and digitalized manufacturing ensure that every single cell maintains exceptional consistency, safety, and dependability — critical for life-supporting and emergency medical equipment.

From project initiation in 2025 to mass production in 2026, the CR123AP medical battery will be simultaneously manufactured at EVE Energy’s dual production bases in Jingmen, China and Penang, Malaysia. This global production footprint enables the company to serve medical customers worldwide, empowering the next wave of medical device upgrades and iterations. With relentless dedication and continuous innovation, EVE Energy remains market-driven and technology-focused, deepening its roots in the medical battery sector — safeguarding life and health with the power of technology and enabling a better life through intelligent green manufacturing.

Edit by paco

Last Update:2026-04-17 08:22:57